Shi Hao,Lyu Zhibao,Chen Zhou.Efficacy and safety of doxycycline injection for marcocystic and mixed-cystic lymphatic malformations in children[J].Journal of Clinical Pediatric Surgery,2022,21(06):558-561.[doi:10.3760/cma.j.cn101785-202104014-011]
多西环素注射治疗儿童大囊型和混合型囊性淋巴管畸形的疗效与安全性探讨
- Title:
- Efficacy and safety of doxycycline injection for marcocystic and mixed-cystic lymphatic malformations in children
- 关键词:
- 多西环素/副作用; 淋巴管畸形/药物疗法; 淋巴管畸形/外科学; 治疗结果; 儿童
- Keywords:
- Doxycycline/AE; Lymphatic Abnormalities/DT; Lymphatic Abnormalities/SU; Treatment Outcome; Child
- 摘要:
- 目的 探讨多西环素注射治疗儿童大囊型和混合型囊性淋巴管畸形的有效性及安全性。方法 回顾性分析2018年9月至2020年12月上海市儿童医院/上海交通大学附属儿童医院普外科收治，并进行多西环素注射治疗的13例大囊型和混合型囊性淋巴管畸形患儿临床资料。患儿均经术前超声及MRI明确诊断和分类。其中男6例，女7例；年龄（3.9±3.6）岁（3个月至13岁）。均全身麻醉后在超声/腹腔镜引导下穿刺、引流囊液，并注射多西环素。术后透视评估囊腔范围，并确认药物无溢出。术后4~6周进行初次随访。收集术前、术后影像学资料评价疗效，将疗效分为治愈（体积减小>90%）、有效（体积减小>50%）、部分有效（体积减小<50%）、无效（体积减小<10%或体积无减小）。如第一次注射后疗效未达到有效标准，则予重复注射。若再次注射后仍疗效欠佳，则予手术治疗。结果 13例中，病变位于头颈部7例，腋下1例，上臂1例，胸壁1例，腹膜后2例，腘窝1例；其中1例有头颈部手术史。随访时间（9±6.17）个月（4~27个月）。总有效率为100%，治愈率为69.2%。部分患儿术后出现肿胀、疼痛或呕吐，均自行缓解或经对症治疗后缓解；1例出现囊内出血，予止血治疗后好转。13例均未出现四环素牙或神经损伤。结论 多西环素注射治疗大囊型和混合型囊性淋巴管畸形效果满意，不良反应较少。
- Abstract:
- Objective To explore the efficacy and safety of doxycycline injection for macrocystic and mixed-cystic lymphatic malformations in children.Methods From September 2018 to December 2020, retrospective review of clinical data was performed for 13 children hospitalized with marcocystic and mixed-cystic lymphatic malformations receiving doxycycline injection.There were 6 boys and 7 girls with an average age of (3.9±3.6)(0.25-13) years.Preoperative ultrasound and magnetic resonance imaging (MRI) confirmed the diagnosis and classification.After general anesthesia, cyst was punctured, fluid drained and drug injected under ultrasound/laparoscopic guidance.Fluoroscopy was performed after injection to further evaluate the range of cysts and confirm that there was no drug overflow.During an initial follow-up period of 4-6 weeks after injection, physical and imaging examinations were performed.Based upon a comparison of preoperative and postoperative imaging data, the clinical responses were characterized as cure (volume reduction> 90% or surface invisible), effective (volume reduction> 50%), partially effective (volume reduction <50%) and no response.If the efficacy failed to reach the effective standard (no response or no change in appearance), protocol was repeated.Surgery was performed if re-injection remained ineffective.Results The lesions were located in head and neck (n=7), armpit (n=1), upper arm (n=1), chest wall (n=1), retroperitoneum (n=2) and popliteal fossa (n=1).One child had an operative history of head and neck.There was an average of 19(1.46±0.77) injections.The average follow-up period was (9±6.17)(4-27) months.The overall effective and cure rate was 100% and 69.2% respectively.Swelling, pain and vomiting after injection were relieved spontaneously or symptomatically.One case of hemorrhage in cyst improved after hospitalization for hemostasis.None of them had tetracycline tooth or nerve damage.Conclusion Doxycycline injection is effective for macrocystic and mixed-cystic lymphatic malformations with few adverse reactions.
参考文献/References:
[1] Kulungowski AM, Patel M.Lymphatic malformations[J].Semin Pediatr Surg, 2020, 29(5):150971.DOI:10.1016/j.sempedsurg.2020.150971.
[2] 王燕妮, 齐鸿燕, 张学军.B超引导下微创负压抽吸技术治疗儿童肢体淋巴管畸形的疗效探讨[J].临床小儿外科杂志, 2019, 18(3):221-224.DOI:10.3969/j.issn.1671-6353.2019.03.012.Wang YN, Qi HY, Zhang XJ.Efficacy of mini-invasive negative pressure aspiration guided by B-ultrasound for limb lymphatic malformation in children[J].J Clin Ped Sur, 2019, 18(3):221-224.DOI:10.3969/j.issn.1671-6353.2019.03.012.
[3] Mimura H, Akita S, Fujino A, et al.Japanese Clinical Practice Guidelines for Vascular Anomalies 2017[J].Pediatr Int, 2020, 62(3):257-304.DOI:10.1111/ped.14077.
[4] 中华医学会整形外科分会血管瘤和脉管畸形学组.血管瘤和脉管畸形的诊断及治疗指南(2019版)[J].组织工程与重建外科杂志, 2019, 15(5):277-317.DOI:10.3969/j.issn.1673-0364.2019.05.001.Chinese Society for the Study of Vascular Anomalies (CSSVA).CSSVA Guidelines for Vascular Anomalies 2019[J].Journal of Tissue Engineering and Reconstructive Surgery, 2019, 15(5):277-317.DOI:10.3969/j.issn.1673-0364.2019.05.001.
[5] Burrows PE, Mitri RK, Alomari A, et al.Percutaneous sclerotherapy of lymphatic malformations with doxycycline[J].Lymphatic Research and Biology, 2008, 6(3-4):209-216.DOI:10.1089/lrb.2008.1004.
[6] Zamora AK, Barry WE, Nowicki D, et al.A multidisciplinary approach to management of abdominal lymphatic malformations[J].J Pediatr Surg, 2021, 56(8):1425-1429.DOI:10.1016/j.jpedsurg.2020.10.007.
[7] Bouwman FCM, Kooijman SS, Verhoeven BH, et al.Lymphatic malformations in children:treatment outcomes of sclerotherapy in a large cohort[J].Eur J Pediatr, 2021, 180(3):959-966.DOI:10.1007/s00431-020-03811-4.
[8] Luks VL, Kamitaki N, Vivero MP, et al.Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA[J].J Pediatr, 2015, 166(4):1048-1054.DOI:10.1016/j.jpeds.2014.12.069.
[9] Fereydooni A, Dardik A, Nassiri N.Molecular changes associated with vascular malformations[J].J Vasc Surg, 2019, 70(1):314-326.e311.DOI:10.1016/j.jvs.2018.12.033.
[10] Molitch HI, Unger EC, Witte CL, et al.Percutaneous sclerotherapy of lymphangiomas[J].Radiology, 1995, 194(2):343-347.DOI:10.1148/radiology.194.2.7529933.
[11] Shaye DA, Burks CA, Gadkaree SK, et al.Self-compounded doxycycline sclerotherapy for the treatment of lymphatic malformations in low-resource settings[J].World J Surg, 2020, 44(11):3616-3619.DOI:10.1007/s00268-020-05667-z.
[12] Lee CZ, Xu B, Hashimoto T, et al.Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model[J].Stroke, 2004, 35(7):1715-1719.DOI:10.1161/01.STR.0000129334.05181.b6.
[13] Wiegand S, Eivazi B, Zimmermann AP, et al.Sclerotherapy of lymphangiomas of the head and neck[J].Head Neck, 2011, 33(11):1649-1655.DOI:10.1002/hed.21552.
[14] Cheng J.Doxycycline sclerotherapy in children with head and neck lymphatic malformations[J].Journal of Pediatric Surgery, 2015, 50(12):2143-2146.DOI:10.1016/j.jpedsurg.2015.08.051.
[15] Markovic JN, Nag U, Shortell CK.Safety and efficacy of foam sclerotherapy for treatment of low-flow vascular malformations in children[J].J Vasc Surg Venous Lymphat Disord, 2020, 8(6):1074-1082.DOI:10.1016/j.jvsv.2019.11.023.
[16] 杨耀武, 郑家伟, 孙沫逸, 等.聚桂醇硬化剂治疗口腔颌面部血管瘤和脉管畸形专家共识[J].中国口腔颌面外科杂志, 2018, 16(3):275-278.DOI:10.19438/j.cjoms.2018.03.017.Yang YW, Zheng JW, Sun MY, et al.Expert consensus on the treatment of oral and maxillofacial hemangiomas and vascular malformations by lauromacrogol sclerotherapy[J].China J Oral Maxillofac Surg, 2018, 16(3):275-278.DOI:10.19438/j.cjoms.2018.03.017.
[17] Bai T, Liu Y, Jiang W, et al.A Review of sclerosing foam stability in the treatment of varicose veins[J].Dermatol Surg, 2020, 46(2):249-257.DOI:10.1097/dss.0000000000002039.
[18] Shergill A, John P, Amaral JG.Doxycycline sclerotherapy in children with lymphatic malformations:outcomes, complications and clinical efficacy[J].Pediatric Radiology, 2012, 42(9):1080-1088.DOI:10.1007/s00247-012-2406-2.
备注/Memo
收稿日期:2021-04-09。
基金项目:上海市儿童医院临床研究培育专项重点项目（2020YLYM02）
通讯作者:陈舟,Email:chenz@shchildren.com.cn